BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 33428807)

  • 1. Breast cancer stem cells: A review of their characteristics and the agents that affect them.
    Shan NL; Shin Y; Yang G; Furmanski P; Suh N
    Mol Carcinog; 2021 Feb; 60(2):73-100. PubMed ID: 33428807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Cancer Stem Cells as the Key Driver of Carcinogenesis and Therapeutic Resistance.
    Eid RA; Alaa Edeen M; Shedid EM; Kamal ASS; Warda MM; Mamdouh F; Khedr SA; Soltan MA; Jeon HW; Zaki MSA; Kim B
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Notch Signaling in Breast Cancer: A Role in Drug Resistance.
    BeLow M; Osipo C
    Cells; 2020 Sep; 9(10):. PubMed ID: 33003540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-24 induces chemotherapy resistance and hypoxic advantage in breast cancer.
    Roscigno G; Puoti I; Giordano I; Donnarumma E; Russo V; Affinito A; Adamo A; Quintavalle C; Todaro M; Vivanco MD; Condorelli G
    Oncotarget; 2017 Mar; 8(12):19507-19521. PubMed ID: 28061479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YB-1 interplays with ERα to regulate the stemness and differentiation of ER-positive breast cancer stem cells.
    Yang F; Chen S; He S; Huo Q; Hu Y; Xie N
    Theranostics; 2020; 10(8):3816-3832. PubMed ID: 32206124
    [No Abstract]   [Full Text] [Related]  

  • 6. Overexpression of PER3 Inhibits Self-Renewal Capability and Chemoresistance of Colorectal Cancer Stem-Like Cells via Inhibition of Notch and β-Catenin Signaling.
    Zhang F; Sun H; Zhang S; Yang X; Zhang G; Su T
    Oncol Res; 2017 May; 25(5):709-719. PubMed ID: 27983919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the perpetrator: breast cancer stem cell therapeutics.
    Pal A; Valdez KE; Carletti MZ; Behbod F
    Curr Drug Targets; 2010 Sep; 11(9):1147-56. PubMed ID: 20545606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer stem cells: a potential target for cancer therapy.
    Qiu H; Fang X; Luo Q; Ouyang G
    Cell Mol Life Sci; 2015 Sep; 72(18):3411-24. PubMed ID: 25967289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer stem cells: the promise and the potential.
    Ajani JA; Song S; Hochster HS; Steinberg IB
    Semin Oncol; 2015 Apr; 42 Suppl 1():S3-17. PubMed ID: 25839664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Potential, Challenges and Future Perspective of Cancer Stem Cells in Translational Oncology: A Critical Review.
    Shukla G; Khera HK; Srivastava AK; Khare P; Patidar R; Saxena R
    Curr Stem Cell Res Ther; 2017; 12(3):207-224. PubMed ID: 27804866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human non-small cell lung cancer expresses putative cancer stem cell markers and exhibits the transcriptomic profile of multipotent cells.
    Zakaria N; Yusoff NM; Zakaria Z; Lim MN; Baharuddin PJ; Fakiruddin KS; Yahaya B
    BMC Cancer; 2015 Feb; 15():84. PubMed ID: 25881239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pancreatic cancer stem cells: emerging target for designing novel therapy.
    Li Y; Kong D; Ahmad A; Bao B; Sarkar FH
    Cancer Lett; 2013 Sep; 338(1):94-100. PubMed ID: 22445908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic Strategies for Targeting Ovarian Cancer Stem Cells.
    Yang W; Kim D; Kim DK; Choi KU; Suh DS; Kim JH
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34064635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Let-7d miRNA Shows Both Antioncogenic and Oncogenic Functions in Osteosarcoma-Derived 3AB-OS Cancer Stem Cells.
    Di Fiore R; Drago-Ferrante R; Pentimalli F; Di Marzo D; Forte IM; Carlisi D; De Blasio A; Tesoriere G; Giordano A; Vento R
    J Cell Physiol; 2016 Aug; 231(8):1832-41. PubMed ID: 26679758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-10b expression in breast cancer stem cells supports self-renewal through negative PTEN regulation and sustained AKT activation.
    Bahena-Ocampo I; Espinosa M; Ceballos-Cancino G; Lizarraga F; Campos-Arroyo D; Schwarz A; Maldonado V; Melendez-Zajgla J; Garcia‐Lopez P
    EMBO Rep; 2016 May; 17(5):648-58. PubMed ID: 27113763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphosulindac (OXT-328) selectively targets breast cancer stem cells in vitro and in human breast cancer xenografts.
    Zhu C; Cheng KW; Ouyang N; Huang L; Sun Y; Constantinides P; Rigas B
    Stem Cells; 2012 Oct; 30(10):2065-75. PubMed ID: 22653497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic implications of cellular and molecular biology of cancer stem cells in melanoma.
    Kumar D; Gorain M; Kundu G; Kundu GC
    Mol Cancer; 2017 Jan; 16(1):7. PubMed ID: 28137308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic approaches targeting cancer stem cells.
    Pan Y; Ma S; Cao K; Zhou S; Zhao A; Li M; Qian F; Zhu C
    J Cancer Res Ther; 2018; 14(7):1469-1475. PubMed ID: 30589025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
    Sansone P; Ceccarelli C; Berishaj M; Chang Q; Rajasekhar VK; Perna F; Bowman RL; Vidone M; Daly L; Nnoli J; Santini D; Taffurelli M; Shih NN; Feldman M; Mao JJ; Colameco C; Chen J; DeMichele A; Fabbri N; Healey JH; Cricca M; Gasparre G; Lyden D; Bonafé M; Bromberg J
    Nat Commun; 2016 Feb; 7():10442. PubMed ID: 26858125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem cell programs in cancer initiation, progression, and therapy resistance.
    Huang T; Song X; Xu D; Tiek D; Goenka A; Wu B; Sastry N; Hu B; Cheng SY
    Theranostics; 2020; 10(19):8721-8743. PubMed ID: 32754274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.